Caffeic Acid Phenethyl Ester (CAPE) Induced Apoptosis in Serous Ovarian Cancer OV7 Cells by Deregulation of BCL2/BAX Genes.
Antineoplastic Agents
/ pharmacology
Apoptosis
/ drug effects
Autophagosomes
/ drug effects
Caffeic Acids
/ pharmacology
Cell Line, Tumor
Cell Survival
/ drug effects
Female
Gene Expression
/ drug effects
Humans
Ovarian Neoplasms
/ metabolism
Phenylethyl Alcohol
/ analogs & derivatives
Proto-Oncogene Proteins c-bcl-2
/ genetics
bcl-2-Associated X Protein
/ genetics
CAPE
OV7
apoptosis
caffeic acid phenethyl ester
cytotoxicity
ovarian cancer
Journal
Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009
Informations de publication
Date de publication:
31 Jul 2020
31 Jul 2020
Historique:
received:
13
06
2020
revised:
26
07
2020
accepted:
29
07
2020
entrez:
6
8
2020
pubmed:
6
8
2020
medline:
10
3
2021
Statut:
epublish
Résumé
Ovarian cancer has the worst prognosis among all gynecological cancers. Therefore, it seems reasonable to seek new drugs that may improve the effectiveness of treatment or mitigate the adverse effects of chemotherapy. Caffeic acid phenethyl ester (CAPE) has many beneficial biological properties. The aim of the study was to assess the anticancer properties of CAPE against serum ovarian carcinoma cells. The morphology of the cells was evaluated in H-E staining and in transmission electron microscopy. The cytotoxic and proapoptotic activity of CAPE was investigated by using the XTT-NR-SRB assay, qRT-PCR analysis of BAX/BCL2 expression, and by cytometric evaluation. CAPE causes constriction in OV7 cells, numerous granulomas were observed in the cytoplasm, the cell nuclei were pyknotic. Autophagosomal vacuoles could suggest the occurrence of aponecrosis. CAPE significantly decreased the lysosomal activity and the total synthesis of cellular proteins. CAPE exhibited, dose and time dependent, cytotoxic activity against OV7 serum ovarian cancer cells. In OV7 cells CAPE induced apoptosis via dysregulation of BAX/BCL2 balance, while activated proapoptotic BAX gene expression level was 10 times higher than BCL2.
Identifiants
pubmed: 32752091
pii: molecules25153514
doi: 10.3390/molecules25153514
pmc: PMC7435968
pii:
doi:
Substances chimiques
Antineoplastic Agents
0
Caffeic Acids
0
Proto-Oncogene Proteins c-bcl-2
0
bcl-2-Associated X Protein
0
caffeic acid phenethyl ester
G960R9S5SK
Phenylethyl Alcohol
ML9LGA7468
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Śląski Uniwersytet Medyczny
ID : KNW-1-183/N/8/0 and KNW-1-163/M/9/0
Références
Front Chem. 2014 May 01;2:20
pubmed: 24822174
Invest New Drugs. 2019 Oct;37(5):837-848
pubmed: 30465316
Eur Rev Med Pharmacol Sci. 2012 Dec;16(15):2064-8
pubmed: 23280020
IUBMB Life. 2013 Aug;65(8):716-29
pubmed: 23847086
Postepy Hig Med Dosw (Online). 2015 Dec 16;69:1353-63
pubmed: 26671926
Mol Cell Biochem. 2008 Mar;310(1-2):43-8
pubmed: 18060475
Clin Exp Immunol. 2010 May;160(2):223-32
pubmed: 20059479
Crit Rev Food Sci Nutr. 2016 Oct 2;56(13):2183-90
pubmed: 25365228
Pomeranian J Life Sci. 2015;61(4):411-8
pubmed: 29522663
CA Cancer J Clin. 2011 May-Jun;61(3):183-203
pubmed: 21521830
Drug Des Devel Ther. 2019 Apr 26;13:1335-1345
pubmed: 31118570
Asian Pac J Cancer Prev. 2013;14(10):6159-64
pubmed: 24289642
Molecules. 2020 Jul 31;25(15):
pubmed: 32752091
Phytother Res. 2018 Aug;32(8):1425-1449
pubmed: 29672977
Sci Rep. 2017 Aug 8;7(1):7599
pubmed: 28790461
Exp Ther Med. 2018 Apr;15(4):3404-3412
pubmed: 29545862
Mol Cell Biochem. 2016 Feb;413(1-2):189-98
pubmed: 26838168
Cancer Lett. 2011 Sep 1;308(1):43-53
pubmed: 21570765
Integr Cancer Ther. 2018 Dec;17(4):1247-1259
pubmed: 30246565
Integr Cancer Ther. 2018 Sep;17(3):867-873
pubmed: 29390900
Arch Oral Biol. 2017 Dec;84:94-99
pubmed: 28965045
J Pharm Bioallied Sci. 2015 Apr;7(Suppl 1):S181-3
pubmed: 26015704
Biotech Histochem. 2019 Oct;94(7):491-497
pubmed: 30991851
Lancet Oncol. 2017 Jun;18(6):779-791
pubmed: 28438473
Int J Mol Sci. 2018 Jan 16;19(1):
pubmed: 29337925
J Diet Suppl. 2016;13(3):245-68
pubmed: 25723108
Cancer Prev Res (Phila). 2012 May;5(5):788-97
pubmed: 22562408
Nat Rev Cancer. 2006 Jan;6(1):24-37
pubmed: 16397525
Molecules. 2015 May 20;20(5):9242-62
pubmed: 26007182
Oncotarget. 2017 Jul 25;8(30):50284-50304
pubmed: 28514737
World J Gastroenterol. 2017 Feb 21;23(7):1203-1214
pubmed: 28275300
Molecules. 2017 Sep 15;22(9):
pubmed: 28926932
Biomed Pharmacother. 2018 Mar;99:825-831
pubmed: 29710481
Int J Mol Sci. 2019 Mar 09;20(5):
pubmed: 30857282
J Agric Food Chem. 2001 Nov;49(11):5615-9
pubmed: 11714368
Iran J Pharm Res. 2011 Spring;10(2):321-8
pubmed: 24250361
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
Evid Based Complement Alternat Med. 2017;2017:6793456
pubmed: 28167973
Nat Rev Mol Cell Biol. 2010 Oct;11(10):700-14
pubmed: 20823910
Molecules. 2015 Jul 10;20(7):12576-89
pubmed: 26184141